JPS6237611B2 - - Google Patents
Info
- Publication number
- JPS6237611B2 JPS6237611B2 JP56018429A JP1842981A JPS6237611B2 JP S6237611 B2 JPS6237611 B2 JP S6237611B2 JP 56018429 A JP56018429 A JP 56018429A JP 1842981 A JP1842981 A JP 1842981A JP S6237611 B2 JPS6237611 B2 JP S6237611B2
- Authority
- JP
- Japan
- Prior art keywords
- immune complex
- immune
- protease
- acidic
- human igg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000024781 Immune Complex disease Diseases 0.000 claims description 11
- 108091005508 Acid proteases Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 230000002485 urinary effect Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 description 18
- 108091005804 Peptidases Proteins 0.000 description 18
- 239000004365 Protease Substances 0.000 description 18
- 230000002378 acidificating effect Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 206010043778 thyroiditis Diseases 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 102000004178 Cathepsin E Human genes 0.000 description 1
- 108090000611 Cathepsin E Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000008394 fibrinolytic abnormality Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56018429A JPS57131725A (en) | 1981-02-10 | 1981-02-10 | Remedy for immune complex disease |
| CA000395742A CA1181005A (en) | 1981-02-10 | 1982-02-08 | Therapeutic agent for treatment of allergic diseases, immune complex diseases and tumors |
| AU80290/82A AU531314B2 (en) | 1981-02-10 | 1982-02-09 | Therapeutic agent containing human urinary acid protease |
| CH782/82A CH653557A5 (de) | 1981-02-10 | 1982-02-09 | Zur behandlung von allergischen zustaenden, immunkomplexkrankheiten und tumoren geeignetes therapeutisches mittel. |
| SE8200748A SE455163B (sv) | 1981-02-10 | 1982-02-09 | Uropepsin for anvendning som terapeutikum mot allergiska sjukdomar, immunkomplexsjukdomar och tumorer |
| GB8203682A GB2095993B (en) | 1981-02-10 | 1982-02-09 | Compositions containing human urinary acid protease |
| DE8282100973T DE3273953D1 (en) | 1981-02-10 | 1982-02-10 | Therapeutic agent containing a human urinary pepsin |
| EP82100973A EP0059346B1 (en) | 1981-02-10 | 1982-02-10 | Therapeutic agent containing a human urinary pepsin |
| NL8200509A NL8200509A (nl) | 1981-02-10 | 1982-02-10 | Geneesmiddel voor allergiekwalen, immuuncomplexziekten en tumoren; werkwijze voor het behandelen van patienten die hieraan lijden. |
| IT47761/82A IT1154280B (it) | 1981-02-10 | 1982-02-10 | Agente terapeutico a base di protea si acida e suo impiego in pazienti affetti da disordini allergici,malattie da immuno-complessi e tumori |
| FR8202145A FR2499409A1 (fr) | 1981-02-10 | 1982-02-10 | Agent therapeutique a base d'une protease acide, pour le traitement des troubles allergiques, des maladies avec immunocomplexe et des tumeurs |
| DE19823204631 DE3204631A1 (de) | 1981-02-10 | 1982-02-10 | Therapeutisches mittel und dessen verwendung |
| US06/365,465 US4540569A (en) | 1981-02-10 | 1982-04-05 | Method for treatment of allergic disorders and immune complex diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56018429A JPS57131725A (en) | 1981-02-10 | 1981-02-10 | Remedy for immune complex disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57131725A JPS57131725A (en) | 1982-08-14 |
| JPS6237611B2 true JPS6237611B2 (nl) | 1987-08-13 |
Family
ID=11971396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56018429A Granted JPS57131725A (en) | 1981-02-10 | 1981-02-10 | Remedy for immune complex disease |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS57131725A (nl) |
-
1981
- 1981-02-10 JP JP56018429A patent/JPS57131725A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57131725A (en) | 1982-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Olson | Role of heparin as a protective agent following reduction of renal mass | |
| Morris et al. | Isolation of renin granules from rat kidney cortex and evidence for an inactive form of renin (prorenin) in granules and plasma | |
| Davies et al. | The effect of trypan blue, suramin and aurothiomalate on the breakdown of 125I-labelled albumin within rat liver lysosomes | |
| JPH0544478B2 (nl) | ||
| JPS62174023A (ja) | 抗血液凝固物質、その製法及びそれを有効成分とする抗血液凝固剤 | |
| Bützow et al. | Purification and characterization of placental protein 5 | |
| Coppo et al. | Plasmapheresis in a patient with rapidly progressive idiopathic IgA nephropathy: removal of IgA-containing circulating immune complexes and clinical recovery | |
| US5262178A (en) | Therapeutic use of enkephalinase | |
| España et al. | Complexes of tissue kallikrein with protein C inhibitor in human semen and urine | |
| CA1198672A (en) | Fibrinolytically active agent and a method for the preparation thereof | |
| US4479937A (en) | Process of treating inflammation with human urinary thiol protease inhibitor | |
| JPS6237611B2 (nl) | ||
| US4540569A (en) | Method for treatment of allergic disorders and immune complex diseases | |
| Rosenblum et al. | Hepatobiliary and pancreatic clearance of circulating pancreatic amylase | |
| Mackenzie et al. | Rapid renal failure in a case of multiple myeloma: the role of Bence Jones proteins | |
| US5403585A (en) | Therapeutic use of enkephalinase | |
| Bocci | Catabolism of plasma proteins | |
| Grant et al. | Identification of a defence mechanism in vivo against the leakage of enterokinase into the blood | |
| JPS6238329B1 (nl) | ||
| CA1207262A (en) | Human leucocyte pepsin-like enzyme, method for preparation of the enzyme, and method and therapeutic agent for treating allergic disorders, immune complex diseases and tumors containing the same as an effective ingredient | |
| CA1222693A (en) | Membrane-associated proteins (mp.sub.2), a process for obtaining them, and their use | |
| Largman et al. | Clearance and metabolism of circulating pancreatic proelastase in the rat | |
| US3522229A (en) | Glycoprotein from saliva or salivary glands having gastric acid secretion inhibitory as well as anti-ulcerative activity and method of collecting the same | |
| JPS60188400A (ja) | 組織蛋白ｐｐ↓１↓９およびその取得方法 | |
| US6103691A (en) | Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins |